modafinil has been researched along with Sarcoidosis in 2 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Sarcoidosis: An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a double-blind, placebo-controlled, crossover study of sarcoidosis patients followed up in one sarcoidosis clinic Sarcoidosis patients with fatigue received either armodafinil or placebo with eight weeks of therapy for each arm and a two week washout period before crossover to the other treatment." | 9.17 | Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. ( Baughman, RP; Lower, EE; Malhotra, A; Surdulescu, V, 2013) |
| "This was a double-blind, placebo-controlled, crossover study of sarcoidosis patients followed up in one sarcoidosis clinic Sarcoidosis patients with fatigue received either armodafinil or placebo with eight weeks of therapy for each arm and a two week washout period before crossover to the other treatment." | 5.17 | Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. ( Baughman, RP; Lower, EE; Malhotra, A; Surdulescu, V, 2013) |
| "Trial evidence for treating fatigue as a manifestation of sarcoidosis is limited and requires further investigation." | 2.55 | Managing fatigue in sarcoidosis - A systematic review of the evidence. ( Atkins, C; Wilson, AM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, C | 1 |
| Wilson, AM | 1 |
| Lower, EE | 1 |
| Malhotra, A | 1 |
| Surdulescu, V | 1 |
| Baughman, RP | 1 |
1 review available for modafinil and Sarcoidosis
| Article | Year |
|---|---|
Managing fatigue in sarcoidosis - A systematic review of the evidence.
Topics: Adalimumab; Antirheumatic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Exercise | 2017 |
1 trial available for modafinil and Sarcoidosis
| Article | Year |
|---|---|
Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Cross-Over Studies; Dose-Response Re | 2013 |